ENG and glioblastoma: In this study, the higher expression of MVD-CD105 in recurrent GBM specimens seems to be associated with worse progression-free survival and overall survival in patients treated with anti-angiogenics upon recurrence, whereas CD105 expression in the primary tumor had no impact on survival outcomes.